Charles River Laboratories Intl (CRL) 34.54 -1.04

Charles River Laboratories International, Inc.
(CRL) 34.54 -1.04

Last Trade:	33.77	Day Range:	33.67 - 34.57
Trade Time:	04:02PM	52wk Range:	25.52 - 42.68
Prev. Close:	34.81	Market Cap:	1.67B
Open:	34.51	Div Yield:	0
Volume:	278443	PE:	-90
EPS:	-3.68

The Latest On CRL

Holder & Obama's Propaganda is "Belied by a Troublesome Little Thing Called Facts" 1/30/12 6:32am

Benzinga's M&A Chatter for Tuesday January 10, 2012 1/10/12 6:43pm

JP Morgan Reiterates BioMimetic Therapeutics Neutral 1/4/12 1:05pm

UPDATE: Citigroup Maintains Neutral, Lowers PT to $31 on Charles River Laboratories 12/15/11 7:33am

Citigroup Lowers PT on Charles River Laboratories to $31 12/15/11 5:50am

UPDATE: Deutsche Bank Lowers PT on Charles River Laboratories to $28 12/14/11 11:25am

Deutsche Bank Maintains Hold After Charles River Releases 2012 Guidance 12/14/11 7:49am

Charles River Sees 2012 Non-GAAP EPS of $2.60-2.70 vs 2.67 Est 12/14/11 7:01am

Notable Call Options Activity in Charles River Laboratories 12/12/11 10:07am

Sterne Agee Maintains Buy, PT of $43 on Charles River Laboratories 12/5/11 7:38am

UPDATE: Piper Jaffray Upgrades Arena Pharma to Overweight and Raises PT to $3 11/28/11 7:39am

UPDATE: Credit Suisse Lowering Price Target on Alimera Sciences 11/15/11 8:14am

Holder & Obama's Propaganda is "Belied by a Troublesome Little Thing Called Facts" 1/30/12

Benzinga's M&A Chatter for Tuesday January 10, 2012 1/10/12

JP Morgan Reiterates BioMimetic Therapeutics Neutral 1/4/12

UPDATE: Citigroup Maintains Neutral, Lowers PT to $31 on Charles River Laboratories 12/15/11

Citigroup Lowers PT on Charles River Laboratories to $31 12/15/11

UPDATE: Deutsche Bank Lowers PT on Charles River Laboratories to $28 12/14/11

Deutsche Bank Maintains Hold After Charles River Releases 2012 Guidance 12/14/11

Charles River Sees 2012 Non-GAAP EPS of $2.60-2.70 vs 2.67 Est 12/14/11

Notable Call Options Activity in Charles River Laboratories 12/12/11

Sterne Agee Maintains Buy, PT of $43 on Charles River Laboratories 12/5/11

UPDATE: Piper Jaffray Upgrades Arena Pharma to Overweight and Raises PT to $3 11/28/11

UPDATE: Credit Suisse Lowering Price Target on Alimera Sciences 11/15/11

Benzinga's M&A Chatter for Tuesday January 10, 2012 1/10/12

Who Wants to Buy Some Drugs? 7/19/11

A Peek Into The Market Before The Trading Starts 12/27/10

Arena Pharmaceuticals Set To Reopen 8:15am After FDA End-Of-Review (ARNA) 12/22/10

Bullish Bet on Charles River Labs 5/5/10

21 Long Trade Setups with Stop-Losses 4/1/10

Trade Ideas for February 9, 2010 2/9/10

JP Morgan Reiterates BioMimetic Therapeutics Neutral 1/4/12

UPDATE: Citigroup Maintains Neutral, Lowers PT to $31 on Charles River Laboratories 12/15/11

Citigroup Lowers PT on Charles River Laboratories to $31 12/15/11

UPDATE: Deutsche Bank Lowers PT on Charles River Laboratories to $28 12/14/11

Deutsche Bank Maintains Hold After Charles River Releases 2012 Guidance 12/14/11

Sterne Agee Maintains Buy, PT of $43 on Charles River Laboratories 12/5/11

UPDATE: Piper Jaffray Upgrades Arena Pharma to Overweight and Raises PT to $3 11/28/11

UPDATE: Credit Suisse Lowering Price Target on Alimera Sciences 11/15/11

Sterne Agee Initiates Charles River Laboratories Coverage: Buy, $43 PT 11/14/11

McNicoll Lewis Vlak Raises PT on Transcept Pharmaceuticals to $8 9/28/11

Jefferies Has Hold On Charles River Laboratories 8/24/11

UPDATE: Jefferies Lowers PT on Charles River Laboratories to $33 8/9/11

Trade CRL
NOW!

Partner Headlines

The Cutting Edge in Drug Development 2/1/12

10 Top Morningstar M&A Stock Picks 1/20/12

The Long-Term Play In Lab Work (BBH, CRL, ICLR, PRXL, WX) 1/16/12

Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" 1/11/12

Stocks I Can Buy Much Cheaper Than Halvorsen Did 1/11/12

Ken Heebner Top Holdings: AAPL Is a Buy at $380 1/11/12

Company News for January 11, 2012 - Corporate Summary 1/11/12

Charles River rises on sale talk 1/10/12

Charles River Guides Higher - Analyst Blog 12/16/11

PPDI Shareholders Nod to Merger - Analyst Blog 12/2/11

Charles River Misses Overall - Analyst Blog 11/3/11

Press Releases

Government of Canada Seeking Interest in AECL Laboratories 2/9/12 Marketwire Story

Charles River to Present at UBS and Leerink Swann Conferences 2/7/12 Business Wire Story

Charles River Schedules Fourth-Quarter and Full-Year 2011 Earnings Release and Conference Call 1/17/12 Business Wire Story

FDA Accepts Resubmission of Lorcaserin New Drug Application 1/10/12 Newswire Story

Charles River to Present at J.P. Morgan Healthcare Conference 1/9/12 Business Wire Story

Arena Submits Response to FDA Complete Response Letter for Lorcaserin 1/5/12 ACN Newswire Story

Arena Submits Response to FDA Complete Response Letter for Lorcaserin 1/3/12 Newswire Story

Jericho Systems JAzP Secures Access to SharePoint 2010 12/15/11 Business Wire Story

Charles River Provides 2012 Financial Guidance 12/14/11 Business Wire Story

Charles River Schedules 2012 Guidance Release and Conference Call 11/29/11 Business Wire Story

Drug Safety and Preclinical Sciences Leader Joins MPI Research 11/28/11 Business Wire Story

pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN® for DME 11/11/11 Business Wire Story

Get the latest CRL stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Charles River Laboratories International, Inc. stock price.

Charles River Laboratories International, Inc. by YCharts